Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E194.91 EPS (ttm)0.72 Insider Own0.70% Shs Outstand229.95M Perf Week-11.07%
Market Cap32.31B Forward P/E21.30 EPS next Y6.60 Insider Trans-19.50% Shs Float222.94M Perf Month-1.69%
Income145.20M PEG9.86 EPS next Q1.18 Inst Own98.30% Short Float2.60% Perf Quarter-2.07%
Sales2.70B P/S11.95 EPS this Y-79.50% Inst Trans0.03% Short Ratio3.33 Perf Half Y-20.13%
Book/sh35.82 P/B3.92 EPS next Y30.29% ROA1.10% Target Price195.74 Perf Year-18.53%
Cash/sh4.47 P/C31.45 EPS next 5Y19.77% ROE1.80% 52W Range124.16 - 208.88 Perf YTD-26.33%
Dividend- P/FCF- EPS past 5Y5.10% ROI1.60% 52W High-30.48% Beta0.88
Dividend %- Quick Ratio3.00 Sales past 5Y36.90% Gross Margin91.80% 52W Low16.96% ATR5.23
Employees2924 Current Ratio3.50 Sales Q/Q16.80% Oper. Margin22.10% RSI (14)45.79 Volatility3.54% 3.36%
OptionableYes Debt/Eq0.40 EPS Q/Q-9.40% Profit Margin5.40% Rel Volume1.58 Prev Close140.53
ShortableYes LT Debt/Eq0.40 EarningsApr 28 BMO Payout0.00% Avg Volume1.74M Price145.22
Recom2.00 SMA20-4.40% SMA500.71% SMA200-12.04% Volume1,145,590 Change3.34%
Mar-08-16Downgrade Robert W. Baird Outperform → Neutral $221 → $170
Feb-25-16Initiated Citigroup Buy $165
Feb-04-16Reiterated UBS Buy $222 → $200
Feb-04-16Reiterated Barclays Equal Weight $202 → $175
Jan-20-16Initiated Credit Suisse Neutral
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $225
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Dec-11-15Reiterated Stifel Buy $250 → $245
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-14-15Downgrade Barclays Overweight → Equal Weight $220 → $205
Sep-01-15Initiated Raymond James Strong Buy $225
Jul-31-15Reiterated UBS Buy $220 → $223
Jul-31-15Reiterated Stifel Buy $239 → $257
Jul-31-15Reiterated Brean Capital Buy $213 → $221
Jul-27-15Resumed JP Morgan Overweight
May-07-15Upgrade Nomura Neutral → Buy
May-07-15Reiterated Brean Capital Buy $215 → $213
Jan-30-15Reiterated Stifel Buy $230 → $236
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
May-02-16 03:22PM  Biotech ETFs Sink on Mixed Q1 Results Zacks
10:44AM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
May-01-16 10:50AM  Analysts Make Major Changes to Top Biotech Ratings at 24/7 Wall St.
Apr-29-16 05:05PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08:11AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : April 29, 2016 at Capital Cube
Apr-28-16 05:17PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online -5.47%
04:57PM  How Did XBIs Large Caps Perform? Market Realist
02:21PM  Edited Transcript of ALXN earnings conference call or presentation 28-Apr-16 2:00pm GMT Thomson Reuters StreetEvents
01:40PM  Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View Zacks
01:03PM  Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Reuters
08:30AM  Alexion (ALXN) Misses on Q1 Earnings and Revenues Zacks
07:22AM  [$$] Alexion Profit Declines but Revenue Rises at The Wall Street Journal
07:07AM  Q1 2016 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:47AM  Alexion misses Street 1Q forecasts AP
06:30AM  Alexion Reports First Quarter 2016 Results Business Wire
Apr-26-16 06:53PM  Alexion (ALXN) Q1 Earnings: What's in Store for the Stock? Zacks
04:32PM  Whirlpool and Corning slide, DuPont and Supervalu rise AP
10:05AM  4 Biotechs That Will Escape Weak Seasonal Trends for the Sector at 24/7 Wall St.
Apr-14-16 07:04AM  Why Has Teva Pharmaceutical Targeted Orphan Diseases?
Apr-13-16 01:26PM  Analyzing XLV: Why Did It Remain Stable and Positive?
Apr-12-16 10:00AM  Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016 Business Wire
Apr-09-16 09:12AM  9 Drugs That Cost Medicare a Fortune at Motley Fool
Apr-07-16 04:26PM  Alexion Pharma (ALXN) Stock Receives 'Market Perform' Rating at BMO Capital at TheStreet -5.73%
11:51AM  Is Biotech Back? at Barrons.com
11:04AM  Shire at Discount on Price-to-Earnings Basis: A Good Opportunity?
Apr-06-16 01:04AM  Understanding Acthars Big Contribution to Mallinckrodts Top-line +6.07%
Apr-05-16 03:36PM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : April 5, 2016
12:59PM  Under the Radar: Hudson's Bay & biotech
12:21PM  Alexion Pharmaceuticals New Data from Phase 2 Trial of Strensiq
Apr-04-16 08:07AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : April 4, 2016
06:30AM  Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physical Function in Children with Hypophosphatasia (HPP) Receiving Long-Term Treatment with Strensiq® (asfotase alfa) Business Wire
Apr-02-16 02:03PM  The Secrets Out: These Biotech Marvels Have Fallen Too Far
04:48AM  PRHSX: T. Rowe Health Sciences Fund Top 5 Holdings Analysis at Investopedia
Mar-31-16 02:04PM  5 Punished Stocks: Are They Bargains? (ENDP,VRTX) at Investopedia
Mar-29-16 03:35PM  Alexion Pharmaceuticals' Kanuma Gains Approval in Japan
12:07PM  [$$] Moderna Therapeutics Hires Former Alexion Pharma Executive as Chief Business Officer at The Wall Street Journal
Mar-28-16 06:58AM  Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) at noodls
06:30AM  Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Business Wire
Mar-24-16 08:47AM  Why Alexion Pharmaceuticals (ALXN) Stock Might be a Great Pick
Mar-23-16 07:00AM  8 Wide-Moat Stocks of Tomorrow at Morningstar
Mar-22-16 05:23PM  Stocks Close Mixed; Nike Slips After Hours On Sales Miss
01:24PM  Stocks Recover Off Lows; Health Care Names Bounce Again
Mar-18-16 07:19PM  Do You Own Any Of These Top Sector Funds?
06:25PM  The S&P 500 Just Broke Into Positive Territory for 2016 at Fortune
Mar-17-16 02:29PM  Ireland's Growing GDP Boosted by Foreign Direct Investment at TheStreet
Mar-16-16 03:11PM  How Are Analysts Rating Valeant after the Turmoil?
03:10PM  Will Valeants Share Price Recover from the Recent Fall?
03:10PM  Valeants Preliminary 4Q15 Revenue and Earnings
Mar-15-16 09:08PM  Rare Disease Portfolio Helped Sanofi to Offset Falling Diabetes Sales
Mar-14-16 10:21AM  Gilead Sciences: The Best Bet in Biotech, UBS Says at Barrons.com
Mar-11-16 09:02AM  Is This Upstart the Biggest Threat to Alexion Pharmaceuticals? at Motley Fool
Mar-10-16 04:21PM  13 big companies keep growing like crazy at USA TODAY
Mar-08-16 03:03PM  Why Omeros Corporation Dropped 12% in February at Motley Fool -5.73%
12:43PM  Why Omeros Corporation Is Up Today at Motley Fool
05:45AM  Alexion Pharma downgraded by Robert W. Baird
Mar-07-16 08:07AM  BioMarins Naglazyme Sales Dipped by 31.3% Last Year
Mar-03-16 06:16PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
05:15PM  New Data Presented at WORLDSymposium 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma (sebelipase alfa) Business Wire
01:07PM  Endo International Market Cap Fell: Reduced to Mid-Cap
01:06AM  Will Soliriss Label Expansion Fuel Alexions Growth?
Mar-01-16 09:07PM  What Do Analysts Expect from Alexion? +7.12%
09:06PM  Vertex Hopes Label Expansion Will Bring Growth for Kalydeco
07:30PM  SBC-103 (rhNAGLU enzyme) Shows a 26.2 Percent Mean Reduction in Heparan Sulfate in Cerebrospinal Fluid at the Highest Dose Studied in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) in Phase 1/2 Study at Six Months Business Wire
Feb-29-16 07:09PM  Analyzing Alexions Performance on an EV-to-EBITDA Basis
07:09PM  A Buy for Alexion on PE Performance Basis
10:00AM  Alexion to Present at Upcoming Investor Conferences Business Wire
10:00AM  Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
06:00AM  Alexion Employees Across the Globe Join Together to Support Rare Disease Day 2016 Business Wire
Feb-26-16 05:23PM  Oscar worthy stock picks investors should own
05:00PM  The 4 Oscar trades of the season
Feb-25-16 01:32PM  Healthcare-focused Baker Bros. Advisors Top Picks: Incyte, Alexion, ACADIA & More at Insider Monkey
Feb-24-16 09:07AM  Why Are Most Analysts Recommending a Buy for Vertex?
Feb-23-16 12:53PM  How Did Vertex Perform Based on EV-to-EBITDA?
12:53PM  Why Is Vertex Pharmaceuticals Valuation at a Discount?
Feb-19-16 01:43PM  2 Reasons Alexion Pharmaceuticals' Stock Could Rise at Motley Fool
Feb-17-16 07:01PM  UK cost agency queries value of $700,000-a-year Alexion drug Reuters
Feb-12-16 01:04PM  ALEXION PHARMACEUTICALS INC Financials
Feb-11-16 03:31PM  Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta
Feb-09-16 01:48PM  Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Feb-08-16 02:33PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
01:32PM  Alexion Pharmaceuticals' Big Top Foreshadows Big Drop
Feb-05-16 05:56PM  The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release at Motley Fool
01:06PM  How to Play the Biotech Selloff at Barrons.com
10:32AM  Leerink Is Back On Board The Biotech Train
Feb-04-16 10:33AM  Alexion Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers
10:00AM  Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference Business Wire
08:15AM  Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%
Feb-03-16 07:00PM  Lightning Round: This energy stock goes higher at CNBC +6.27%
04:53PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
01:27PM  Edited Transcript of ALXN earnings conference call or presentation 3-Feb-16 3:00pm GMT
01:20PM  Alexion Pharmaceuticals Rides the Earnings Roller Coaster at Barrons.com
10:50AM  Alexion Misses on Earnings and Revenues in Q4, Gives View
08:39AM  [$$] Alexion Pharmaceuticals Revenue Jumps, Profit Falls at The Wall Street Journal
08:00AM  Biotechnology Stocks Technical Snapshot -- Geron, ACADIA Pharma, Alexion Pharma, and Illumina Accesswire
07:55AM  Alexion (ALXN) Misses on Q4 Earnings and Revenues
07:37AM  Morning Movers: Alexion, Merck Drop on Earnings; Atwood Oceanics Gains at Barrons.com
07:07AM  Q4 2015 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open
06:57AM  Alexion tops 4Q profit forecasts
06:53AM  Alexion beats 4Q profit forecasts
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Neill JulieEVP. Global OperationsMar 02Sale149.5565197,35736,034Mar 04 06:21 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 29Sale138.9132945,70116,886Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 29Sale138.91547,50141,579Mar 01 06:34 PM
BELL LEONARDDirectorFeb 29Sale138.923,995554,987742,197Mar 01 06:32 PM
Carmichael ClareEVP, Chief HR OfficerFeb 29Sale138.911,312182,25039,742Mar 01 06:32 PM
Moriarty John BEVP & General CounselFeb 29Sale138.911,201166,83352,278Mar 01 06:32 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 29Sale138.91905125,71443,799Mar 01 06:33 PM
Wagner Heidi LSVP, Global Government AffairsFeb 29Sale138.9154775,98432,390Mar 01 06:34 PM
Hallal DavidCEOFeb 29Sale138.932,014279,800191,012Mar 01 06:32 PM
Sinha VikasEVP & CFOFeb 29Sale138.911,122155,862178,740Mar 01 06:33 PM
MACKAY MARTINEVP & Global Head of R&DFeb 29Sale138.911,000138,91046,785Mar 01 06:34 PM
O'Neill JulieEVP. Global OperationsFeb 29Sale138.9166392,09736,685Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 16Sale143.4918726,83336,633Feb 18 06:29 PM
Hallal DavidCEOFeb 08Sale138.053,946544,763173,026Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 08Sale138.082,633363,57748,501Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 08Sale138.071,474203,51844,704Feb 08 07:56 PM
BELL LEONARDDirectorFeb 08Sale138.0911,4741,584,442746,192Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 08Sale138.052,665367,91134,054Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale138.07942130,06629,937Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale138.07778107,41930,348Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 08Sale138.091,966271,48140,785Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 08Sale137.613,890535,316171,862Feb 08 07:56 PM
Hallal DavidCEOFeb 05Sale141.636,722952,043176,972Feb 08 07:57 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 05Sale143.021,051150,31414,215Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 05Sale143.451,969282,44751,134Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 05Sale143.481,970282,66146,178Feb 08 07:56 PM
BELL LEONARDDirectorFeb 05Sale143.122,136305,702757,666Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 05Sale141.761,993282,53836,719Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale143.14997142,70830,879Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale143.232,080297,91931,126Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 05Sale141.562,005283,82342,751Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 05Sale143.501,954280,404175,752Feb 08 07:56 PM
Hallal DavidCEOFeb 04Sale143.8362990,469142,558Feb 08 07:57 PM
BELL LEONARDDirectorFeb 04Sale143.832,262325,338746,997Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale143.8420729,77426,949Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 04Sale143.8416924,30925,747Feb 08 07:57 PM
Sinha VikasEVP & CFOFeb 04Sale143.83703101,116165,943Feb 08 07:56 PM
BELL LEONARDDirectorDec 29Option Exercise22.9028,968663,367778,227Dec 29 05:03 PM
BELL LEONARDDirectorDec 29Sale190.8028,9685,526,983749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Option Exercise22.904009,160749,659Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Sale190.1540076,060749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Option Exercise22.905,632128,973754,891Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Sale190.005,6321,070,080749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 17Option Exercise22.9070,0001,603,000819,259Dec 21 05:43 PM
BELL LEONARDDirectorDec 17Sale187.6970,00013,137,985749,259Dec 21 05:43 PM
NORBY R DOUGLASDirectorDec 11Sale187.7145,4428,530,12432,481Dec 15 05:36 PM
Moriarty John BEVP & General CounselDec 11Sale182.73943172,31141,340Dec 15 05:35 PM
Veneman Ann MDirectorDec 11Sale187.48895167,7953,252Dec 15 05:36 PM
BELL LEONARDDirectorDec 11Sale187.5621,3193,998,527727,940Dec 15 05:36 PM
Islam SaqibEVP, Chief Strat & Port. Off.Dec 08Sale190.00950180,50036,385Dec 08 07:36 PM
BELL LEONARDDirectorDec 08Sale188.2070,00013,173,840849,088Dec 08 07:36 PM
BELL LEONARDDirectorNov 25Option Exercise22.9035,000801,500954,088Nov 30 05:42 PM
BELL LEONARDDirectorNov 25Sale181.8935,0006,366,288919,088Nov 30 05:42 PM
Thiel CarstenEVP, Chief Commercial OfficerNov 10Sale173.343,000520,02028,018Nov 12 06:25 PM
PARVEN ALVIN SDirectorNov 02Sale178.73895159,9634,645Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Nov 02Sale180.00975175,50037,335Nov 04 05:29 PM
BELL LEONARDDirectorNov 02Sale180.1235,0006,304,200919,088Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Oct 26Sale168.441,558262,43038,310Oct 29 05:17 PM
Thiel CarstenSVP, EMEA & Asia PacificSep 10Sale169.18812137,37129,018Sep 10 08:45 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale179.5536665,7156,464Sep 10 08:45 PM
BELL LEONARDDirectorSep 09Sale180.101,050189,105919,088Sep 10 08:46 PM
O'Neill JulieEVP. Global OperationsSep 02Sale171.76647111,12921,443Sep 10 08:46 PM
Carmichael ClareEVP, Chief HR OfficerSep 01Sale168.6230551,42927,156Sep 03 07:08 PM
Hallal DavidCEOAug 07Sale190.0132962,513143,187Aug 11 05:53 PM
Carmichael ClareEVP, Chief HR OfficerAug 07Sale190.0116330,97227,461Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 07Sale190.0113525,65142,283Aug 11 05:53 PM
BELL LEONARDDirectorAug 07Sale190.011,003190,580919,088Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 05Option Exercise92.6520,0001,853,00042,428Aug 05 06:08 PM
Moriarty John BEVP & General CounselAug 05Sale198.4410,0101,986,37732,418Aug 05 06:08 PM
Carmichael ClareEVP, Chief HR OfficerAug 04Sale196.5218536,35627,624Aug 05 06:09 PM
Hallal DavidCEOAug 04Sale196.52612120,270143,516Aug 05 06:09 PM
BELL LEONARDDirectorAug 04Sale196.522,200432,344920,091Aug 05 06:08 PM
Sinha VikasEVP & CFOAug 04Sale196.52675132,651166,646Aug 05 06:08 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Option Exercise130.2943,5005,667,48876,393Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Sale196.5243,5008,548,41832,893Aug 05 06:09 PM
BELL LEONARDDirectorJun 18Sale179.6327,8355,000,001922,291Jun 19 07:09 PM
Moriarty John BEVP & General CounselJun 11Sale170.00914155,38032,428Jun 12 06:26 PM
Monnet DominiqueSVP, Chief Marketing OfficerMay 20Sale162.4025641,5748,787May 22 05:30 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.334,056650,29832,893May 22 05:30 PM